175 related articles for article (PubMed ID: 8277209)
21. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning.
Thomas SR
Cancer Biother Radiopharm; 2002 Feb; 17(1):71-82. PubMed ID: 11915175
[TBL] [Abstract][Full Text] [Related]
22. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
23. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications.
Bodei L; Paganelli G; Mariani G
J Nucl Med; 2006 Mar; 47(3):375-7. PubMed ID: 16513604
[No Abstract] [Full Text] [Related]
24. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
[TBL] [Abstract][Full Text] [Related]
25. Radionuclide therapy beyond radioiodine.
Gabriel M
Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
[TBL] [Abstract][Full Text] [Related]
26. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
Widel M
Neoplasma; 2017; 64(5):641-654. PubMed ID: 28592116
[TBL] [Abstract][Full Text] [Related]
27. Clinical trials in molecular radiotherapy-Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018.
Falzone N; Gregory R; Aldridge M; Terry SY; Flux G
Br J Radiol; 2019 Aug; 92(1100):20190117. PubMed ID: 30982344
[TBL] [Abstract][Full Text] [Related]
28. Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
DeNardo GL; Schlom J; Buchsbaum DJ; Meredith RF; O'Donoghue JA; Sgouros G; Humm JL; DeNardo SJ
Cancer; 2002 Feb; 94(4 Suppl):1332-48. PubMed ID: 11877764
[TBL] [Abstract][Full Text] [Related]
29. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice.
Pauwels EK; Stokkel MP
Q J Nucl Med; 2001 Mar; 45(1):18-26. PubMed ID: 11456371
[TBL] [Abstract][Full Text] [Related]
30. Tumour therapy with radionuclides: assessment of progress and problems.
Carlsson J; Forssell Aronsson E; Hietala SO; Stigbrand T; Tennvall J
Radiother Oncol; 2003 Feb; 66(2):107-17. PubMed ID: 12648782
[TBL] [Abstract][Full Text] [Related]
31. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
32. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
33. The role of nuclear medicine in modern therapy of cancer.
Kramer-Marek G; Capala J
Tumour Biol; 2012 Jun; 33(3):629-40. PubMed ID: 22446937
[TBL] [Abstract][Full Text] [Related]
34. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
35. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
Emfietzoglou D; Kostarelos K; Sgouros G
J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
[TBL] [Abstract][Full Text] [Related]
36. Contributions of nuclear medicine to the therapy of malignant tumors.
Feinendegen LE
Strahlenther Onkol; 1991 Nov; 167(11):619-27. PubMed ID: 1962275
[TBL] [Abstract][Full Text] [Related]
37. Radiotargeting agents for cancer therapy.
Kassis AI
Expert Opin Drug Deliv; 2005 Nov; 2(6):981-91. PubMed ID: 16296803
[TBL] [Abstract][Full Text] [Related]
38. Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals.
Palmedo H; Bucerius J
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1556. PubMed ID: 15372210
[No Abstract] [Full Text] [Related]
39. Horizons in radionuclide therapy: 1985 update.
Beierwaltes WH
J Nucl Med; 1985 Apr; 26(4):421-7. PubMed ID: 3884750
[TBL] [Abstract][Full Text] [Related]
40. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
Steiner M; Neri D
Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
